Inclusion Criteria

Concurrent Medication:

Allowed:

• Approved drugs at a stabilized dose except those specifically excluded.
• Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis.

Patients must have:

• HIV positivity.
• Absolute CD4 count < 200 cells/mm3.
• Intolerance to or refusal to take AZT, ddI, ddC, or d4T.
• No active opportunistic infection requiring ongoing therapy.
• Life expectancy at least 3 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Neoplasm other than basal cell carcinoma of the skin.
• Clinically significant cardiac disease.
• Anemia.

Concurrent Medication:

Excluded:

• Cytotoxic chemotherapy.
• Corticosteroids.

Patients with the following prior conditions are excluded:

History of myocardial infarction or arrhythmias.

Prior Medication:

Excluded within 2 weeks prior to study entry:

• Any antiretroviral agent.
• Interferon.
• Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic chemotherapy, or neutropenic or nephrotoxic drugs.

Excluded within 30 days prior to study entry:

• Investigational drugs.

Prior Treatment:

Excluded within 2 weeks prior to study entry:

• Radiation therapy. Active drug or alcohol abuse.